| Document |
Document Title |
|
WO/2024/112759A1 |
Compounds are provided according to Formula (I): and pharmaceutically acceptable salts, isotopic variants, and combinations thereof, and pharmaceutical compositions thereof. Compounds of the present disclosure are contemplated useful for...
|
|
WO/2024/112941A1 |
Autonomic dysfunction has been implicated in the pathophysiology of sudden infant death syndrome (SIDS). Butyrylcholinesterase is an enzyme of the cholinergic system, a major branch of the autonomic system and can be used as a measure of...
|
|
WO/2024/111671A1 |
The present invention addresses the problem of providing a method for increasing affinity of a nucleic acid aptamer comprising 7-(2-thienyl)imidazo[4,5-b]pyridine (Ds base) for a target protein. Provided is a nucleic acid aptamer compr...
|
|
WO/2024/086692A3 |
The present disclosure relates to compositions and methods for the treatment of neurological disorders.
|
|
WO/2024/109672A1 |
The present invention belongs to the field of medicine, and specifically relates to a compound represented by a general formula I as shown below or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, a composition comp...
|
|
WO/2024/108659A1 |
The present invention relates to the technical field of pharmaceuticals, and particularly, to use of a lithium-based agent in preparing a medicament for preventing and/or treating sepsis-associated encephalopathy. The lithium-based agent...
|
|
WO/2024/112083A1 |
The present invention relates to a phytosphingosine-3,4-cyclic phosphate compound and a pharmaceutical composition including same as an active ingredient, wherein the phytosphingosine-3,4-cyclic phosphate compound is capable of increasin...
|
|
WO/2024/036250A3 |
Provided herein are adeno-associated virus (AAV) compositions that can express an arylsulfatase A (ARSA) polypeptide in a cell, thereby restoring the ARSA gene function. Also provided are methods of using the AAV compositions, and packag...
|
|
WO/2024/073601A3 |
The present invention provides method of treating a subject afflicted with a movement disorder, comprising administering to the subject a compound having the structure: (Formula 1) wherein R1 is (C2-C12 alkyl), - (alkenyl), - (alkynyl), ...
|
|
WO/2024/108678A1 |
Provided is use of a substance targeting Inx5 gene and/or Inx5 protein in preparing a medicament for treating sleep disorders. By increasing or decreasing the expression of connexin Inx5 in Drosophila melanogaster neurons by means of gen...
|
|
WO/2024/112287A1 |
The present invention relates to benzimidazole derivatives of formula (I) and their mPGES-1 inhibitory activity. The present invention also relates to pharmaceutical compositions containing these benzimidazole derivatives and their use i...
|
|
WO/2024/112731A1 |
Flavone, quinolinone, quinazolinone, and aurone derivatives are disclosed. The compounds have a structure according to formula I or formula II, or a pharmaceutically acceptable salt, hydrate, stereoisomer, or tautomer thereof. The compou...
|
|
WO/2024/112143A1 |
A fusion protein (ndSTAT1-TMD) provided in the present invention can be efficiently delivered to the nucleus of cells without affecting cytotoxicity and a TcR-mediated signaling event. In addition, the fusion protein provided in the pres...
|
|
WO/2024/109952A1 |
Provided is a non-covalent dimer cation of the present application, which is a cation as shown in the drawing of the abstract, a tautomer thereof, or a stereoisomer thereof. Provided is a salt of the present application, comprising a cat...
|
|
WO/2024/110520A1 |
The present invention is directed to a method for preparing a THC-reduced cannabis plant extract by mixing cannabis plant material with an aqueous organic solvent composition, optionally adjust- ting the pH of the aqueous plant extract t...
|
|
WO/2024/073664A3 |
This application relates to, in part, modified Botulinum Neurotoxins (BoNTs) comprising modified BoNT/A2 receptor binding domains with increased receptor binding activity, and methods of treatment using the modified BoNT.
|
|
WO/2024/108386A1 |
The present invention provides use of an anti-MCP1 neutralizing antibody in preparing a medicament for treating systemic inflammation caused by neurodegenerative diseases, and further provides use of the neutralizing antibody in preparin...
|
|
WO/2024/111552A1 |
The present invention provides an oral solid formulation comprising 1-((1R,2R)-2-hydroxy-4,4-dimethyl-1,2,3,4-tetrahydronaphthal
en-1-yl)-3-(2-phenylpyridin-3-yl)urea or a pharmaceutically acceptable salt thereof or a solvate of foregoin...
|
|
WO/2024/110625A1 |
The present invention relates to compositions for use in methods of preventing or treating retinal diseases or disorders of an animal or a human, wherein said compositions comprise complexes comprising (a) a CRALBP protein, and (b) a cog...
|
|
WO/2024/109817A1 |
Purification process for conjugate (S) -3- ( ( ( (S) -1- ( (S) -2- (6-methoxynaphthalen-2-yl) propanoyloxy) ethoxy) carbonyl-amino) methyl) -5-methylhexanoic acid is described herein.
|
|
WO/2024/086770A3 |
This disclosure relates generally to compositions and methods for assessing neuroinflammation based on the presence of absence of somatic mutations. The compositions and methods provided herein are useful for predicting a subject's risk ...
|
|
WO/2024/109671A1 |
Disclosed are Cas9 protein, variants or homologues thereof-specific PROTAC degrader(s) of Formula (I) or a salt, an enantiomer, a stereoisomer, a solvate, or a polymorph thereof, composition comprising the same, and uses thereof. The sai...
|
|
WO/2024/076500A3 |
In some embodiments, a smart cell drug delivery (SmaCD) system is provided. The SmaCD system can comprise an engineered mammalian regulatory immune cell comprising: (a) a chimeric antigen receptor (CAR) comprising a first binding domain ...
|
|
WO/2024/110577A1 |
The present invention relates to a pharmaceutical composition comprising zuclopenthixol, or a pharmaceutically acceptable salt thereof, and a cyclodextrin, wherein the composition exhibits an increased chemical stability of zuclopenthixo...
|
|
WO/2024/110614A1 |
Disclosed herein are compositions comprising a GLP-1 peptide and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid for use as a medicament by oral administration.
|
|
WO/2024/112854A1 |
The present disclosure relates to RIPK2 inhibitors represented by structural formula (I). The disclosure further relates to pharmaceutical composition comprising the RIPK2 inhibitors and methods of treatment of conditions such as inflamm...
|
|
WO/2024/112924A2 |
Disclosed herein are compositions and methods for use in treating Migraine, for example Episodic or Chronic Migraine, including methods comprising GLP-1 agonist administration.
|
|
WO/2024/112847A1 |
Compositions providing stable and protected prebiotic to provide a prebiotic delivery system to fortify feed, food or water sources for digestion activation of a dopamine precursor are disclosed. The compositions provide a protectant mat...
|
|
WO/2024/108501A1 |
A pharmaceutical use of propofol in an anti-anxiety drug, and an anti-anxiety pharmaceutical preparation. The single administration dosage of propofol as an anti-anxiety drug is lower than the single administration dosage of propofol as ...
|
|
WO/2024/108312A1 |
The present invention relates to compositions, methods and uses of Teneurin C-Terminal Associated Peptide (TCAP) as an antagonist of corticotropin-releasing factor (CRF). In some other embodiments the invention relates to methods and use...
|
|
WO/2024/112746A1 |
The present disclosure relates to methods of making N 2 -(3-(2-(2H-1, 2, 3-triazol-2- yl)propan-2-yl)-1-cyclopropyl-1H-pyrazol-5-yl)- N 4-ethyl-5-(trifluoromethyl)pyrimidine-2,4- diamine and intermediates thereof.
|
|
WO/2024/111990A1 |
The present invention relates to an antibody specifically binding to the acid sphingomyelinase (ASM) protein and a use thereof. Particularly, the antibody or antigen-binding fragment thereof according to the present invention binds speci...
|
|
WO/2024/109736A1 |
The present application provides a compound as shown in formula (0), a pharmaceutical composition containing same, a synthesis method therefor and a use thereof. The compound of the present application can significantly reduce the integr...
|
|
WO/2024/112725A1 |
The invention features methods of treating pain, for example pain associated with central sensitization, with phosphosulindac and compositions thereof.
|
|
WO/2024/109824A1 |
Provided is an application of a neural cell population in treating a nerve damage disease, a neurodegenerative disease, a neurodevelopmental disease, or another disorder associated with forebrain neural cell death and/or insufficiency. T...
|
|
WO/2024/112899A1 |
Disclosed are compounds, compositions, and methods useful for preventing or treating a disease which is at least partially mediated by orexin receptor 2.
|
|
WO/2024/108311A1 |
A method of assessing a risk of developing Alzheimer's disease (AD) and of diagnosing AD in a subject comprising: comparing a level of extracellular vesicles (EVs) that are positive for at least one biomarker in a biofluid sample taken f...
|
|
WO/2024/111529A1 |
This agent for increasing brain plasmalogen contains a compound represented by formula (I), a racemic body thereof, or a salt of those. [In formula (I), X represents a carbon atom or an oxygen atom, R1 represents a saturated aliphatic hy...
|
|
WO/2024/112919A1 |
Apparatus and associated methods relate to inducing ectodermal stimulation by substantially continuous topical application of a therapeutic dose of vascular growth induction agent (VGIA) and moisturizing compound. The moisturizing compou...
|
|
WO/2024/111868A1 |
The present invention relates to a newly identified vMSC secretome and use thereof. Unlike conventional MSCs, vMSCs of the present invention, obtained through culturing under specific culture conditions, are novel MSCs in which a CD141 c...
|
|
WO/2024/108295A1 |
Disclosed herein are compositions comprising a cannabichromene-type cannabinoid. More particularly, the present disclosure relates to compositions comprising a cannabichromene-type cannabinoid and a tetrahydrocannabinol-type cannabinoid.
|
|
WO/2024/112947A1 |
The present invention relates to an oral composition for improving, restoring, modulating, or maintaining sleep, the oral composition comprising a flavonoid compound of the presently-defined Formula (I) and one or more carriers or excipi...
|
|
WO/2024/112727A1 |
The invention features methods of treating pain, for example pain associated with central sensitization, with modified NSAIDs, for example phosphosulindac.
|
|
WO/2024/112741A1 |
Methods are provided for identifying a brain cell in a biological sample, based on the methylation status of multiple methylation markers in genomic DNA. Also provided are kits that can be used for such methods.
|
|
WO/2024/112471A2 |
Multilamellar vesicles (MLVs), methods of their manufacture, and applications thereof to the administration of compounds are provided. MLVs packaged with one or more medicinal compounds, including drugs are also provided. Methods for mod...
|
|
WO/2024/112103A1 |
The present invention relates to a novel peptide having the effect of treating neuroinflammatory diseases, and a use thereof, and more specifically, to a novel peptide having an Lipocalin-2 (LCN2) inhibitory activity which is closely rel...
|
|
WO/2024/108269A1 |
The present disclosure relates to compositions, combinations and formulations as well as and methods and uses for enhancing neuronal survival, neurite growth, and myelin formation. The present disclosure also relates to methods and uses ...
|
|
WO/2024/110583A1 |
The invention relates to compounds and compositions that are useful as selective β2-adrenoceptor (β2-AR) antagonists and their use in the treatment and prevention of disease.
|
|
WO/2024/107445A1 |
The present application provides compositions and methods for treating diseases or disorders using a therapeutically effective amount of a serotonergic psychedelic drug and a therapeutically effective amount of a phosphodiesterase type 9...
|
|
WO/2024/106205A1 |
This biological clock regulator contains, as an active ingredient, at least one among bergamot oil, geranium oil, cedarwood virginia oil, citral, and β-caryophyllene, and advances the phase of the expression rhythm of a clock gene.
|
